Items where authors include "Munir, T"

Article

Hillmen, P, Pitchford, A, Bloor, A et al. (29 more authors) (2023) Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 24 (5). pp. 535-552. ISSN 1470-2045

Munir, T, Emmerson, J orcid.org/0000-0002-8198-8043, Hockaday, A et al. (9 more authors) (2022) Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial. British Journal of Haematology, 199 (5). pp. 707-719. ISSN 0007-1048

Pike, A, McKinley, C, Forrest, B et al. (19 more authors) (2022) COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria. The Lancet Haematology, 9 (8). E553-E556. ISSN 2352-3026

Allsup, DJ, Craig, Z orcid.org/0000-0001-9930-6648, Cairns, D orcid.org/0000-0002-2338-0179 et al. (13 more authors) (2022) Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors. American Journal of Hematology, 97 (5). E168-E171. ISSN 0361-8609

Richards, SJ orcid.org/0000-0002-8421-5353, Painter, D, Dickinson, AJ et al. (14 more authors) (2021) The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK’s population‐based haematological malignancy research network 2004‐2018. European Journal of Haematology. ISSN 0902-4441

Allsup, D, Howard, D, Emmerson, J orcid.org/0000-0002-8198-8043 et al. (10 more authors) (2021) COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study. British Journal of Haematology. ISSN 0007-1048

Howard, DR, Hockaday, A, Brown, JM orcid.org/0000-0002-2719-7064 et al. (6 more authors) (2021) A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia. Trials, 22 (1). 38. ISSN 1745-6215

Pike, A, Muus, P, Munir, T et al. (8 more authors) (2020) COVID‐19 infection in patients on anti‐complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience. British Journal of Haematology, 191 (1). E1-E4. ISSN 0007-1048

Macrae, FL orcid.org/0000-0002-7092-0422, Peacock‐Young, B, Bowman, P et al. (12 more authors) (2020) Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab. American Journal of Hematology, 95 (8). pp. 944-952. ISSN 0361-8609

Richards, SJ orcid.org/0000-0002-8421-5353, Dickinson, AJ, Cullen, MJ et al. (8 more authors) (2020) Presentation clinical, haematological and immunophenotypic features of 1081 patients with GPI‐deficient (paroxysmal nocturnal haemoglobinuria) cells detected by flow cytometry. British Journal of Haematology, 189 (5). pp. 954-966. ISSN 0007-1048

Munir, T, Brown, JR, O'Brien, S et al. (17 more authors) (2019) Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. American Journal of Hematology, 94 (12). pp. 1353-1363. ISSN 0361-8609

Holmes, KB, Sadreev, II, Rawstron, AC orcid.org/0000-0003-0798-9790 et al. (4 more authors) (2019) Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells. Oncogenesis, 8. 32. ISSN 2157-9024

Griffin, M, Hillmen, P orcid.org/0000-0001-5617-4403, Munir, T et al. (4 more authors) (2019) Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. Haematologica, 104 (3). e94-e96. ISSN 0390-6078

Varghese, AM, Rawstron, A orcid.org/0000-0003-0798-9790, Newton, D orcid.org/0000-0002-0214-1486 et al. (5 more authors) (2018) Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia. British Journal of Haematology, 182 (6). pp. 927-930. ISSN 0007-1048

Brown, JR, Hillmen, P orcid.org/0000-0001-5617-4403, O'Brien, S et al. (27 more authors) (2018) Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE(TM) study in patients with previously treated CLL/SLL. Leukemia, 32. pp. 83-91. ISSN 0887-6924

Munir, T, Howard, DR orcid.org/0000-0003-3333-9783, McParland, L et al. (12 more authors) (2017) Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. Leukemia, 31 (10). pp. 2085-2093. ISSN 0887-6924

Collett, L, Howard, DR orcid.org/0000-0003-3333-9783, Munir, T et al. (11 more authors) (2017) Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials, 18. 387. ISSN 1745-6215

Oughton, JB orcid.org/0000-0002-2047-804X, Collett, L, Howard, DR orcid.org/0000-0003-3333-9783 et al. (8 more authors) (2017) GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial. Trials, 18. 353. ISSN 1745-6215

Howard, DR orcid.org/0000-0003-3333-9783, Munir, T, McParland, L et al. (12 more authors) (2017) Results of the randomized phase IIB ARCTIC trial of low dose Rituximab in previously untreated CLL. Leukemia, 31. pp. 2416-2425. ISSN 0887-6924

Worrillow, L, Baskaran, P, Care, MA et al. (9 more authors) (2016) An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukemia cases using multiple polymerases. Oncogene, 35 (40). pp. 5328-5336. ISSN 0950-9232

Howard, DR orcid.org/0000-0003-3333-9783, Munir, T, Hockaday, AM et al. (7 more authors) (2016) Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial. Trials, 17. 456. ISSN 1745-6215

Monograph

Howard, DR orcid.org/0000-0003-3333-9783, Munir, T, McParland, L et al. (9 more authors) (2017) Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial. Report. National Institute for Health Research , Health Technology Assessment. ISSN 1366-5278

Conference or Workshop Item

Newton, DJ, McKinley, CE, Ricardo, A et al. (8 more authors) (2017) Assessment of Eculizumab and C5 Levels in PNH Treatment: Molar Ratio of Eculizumab to C5 Level Effectively Predicts Ongoing Dosage Changes in a Cohort of 50 Patients Treated with Eculizumab. In: 59th ASH Annual Meeting Abstracts, 09-12 Dec 2017, Atlanta, GA, USA.

McKinley, CE orcid.org/0000-0003-4006-8846, Richards, SJ, Munir, T et al. (8 more authors) (2017) Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome. In: 59th ASH Annual Meeting, 09-12 Dec 2017, Atlanta, GA, USA.

Rawstron, A, Cohen, D, de Tute, R et al. (8 more authors) (2015) BONE MARROW IS MORE SENSITIVE THAN PERIPHERAL BLOOD FOR DETECTION OF MRD IN CLL AND PROVIDES A MORE RELIABLE PREDICTION OF OUTCOME ACROSS DIFFERENT TREATMENTS. In: European Haematology Association Congress, 11-14 Jun 2015, Vienna, Austria.

Proceedings Paper

Munir, T, Howard, D orcid.org/0000-0003-3333-9783, McParland, L et al. (10 more authors) (2018) Obinutuzumab as consolidation after chemo-immunotherapy is highly effective in achieving MRD clearance from bone marrow and peripheral blood-Initial results of UK NCRI Phase II/III GALACTIC trial. In: British Journal of Haematology. 58th Annual Scientific Meeting of the British Society for Haematology, 16-18 Apr 2018, Liverpool, UK. Wiley , p. 79.

Macrae, F, Bowman, P, Linton, E et al. (13 more authors) (2017) Fibrinogen and Clot Structure Is Affected By Eculizumab in Patients with Paroxysmal Nocturnal Haemoglobinuria. In: Blood. 59th Annual Meeting of the American-Society-of-Hematology, 09-12 Dec 2017, Atlanta, GA. American Society of Hematology , p. 462.

Holmes, K, Lefevre, P, Sadreev, I et al. (4 more authors) (2017) Ibrutinib mediates changes in chromatin structure in chronic lymphocytic leukaemia (CLL): epigenetic studies from the bloodwise TAP IcICLLe trial. In: Leukemia and Lymphoma. XVII International Workshop on Chronic Lymphocytic Leukemia, 12-15 May 2017, New York, USA. Taylor and Francis , pp. 19-20.